nach oben

Erschienen in:

01.08.2017 | Original Research Article

miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma

verfasst von: Christos K. Kontos, Panagiotis Tsiakanikas, Margaritis Avgeris, Iordanis N. Papadopoulos, Andreas Scorilas

Erschienen in: Molecular Diagnosis & Therapy | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Colorectal cancer is one of the most common gastrointestinal diseases and the second leading cause of cancer-associated deaths among adults. miR-15a-5p is a post-transcriptional regulator of the proto-oncogene MYB, a transcription factor essential for prolonged cancer cell proliferation and survival. In the current study, we assessed the potential diagnostic and prognostic utility of miR-15a-5p expression in colorectal adenocarcinoma.

Methods

To accomplish this goal, total RNA was extracted from 182 colorectal adenocarcinoma specimens and 86 non-cancerous colorectal mucosae. After polyadenylation by poly(A) polymerase and subsequent reverse transcription with an oligo-dT adapter primer, miR-15a-5p expression was analyzed using an in-house developed reverse transcription quantitative real-time PCR method, based on SYBR Green chemistry. SNORD43 (RNU43) was used as an internal control gene.

Results

miR-15a-5p was significantly upregulated in colorectal tumors compared to non-cancerous colorectal mucosae, while ROC analysis suggested its potential use for diagnostic purposes. Moreover, miR-15a-5p overexpression predicts poor disease-free survival (DFS) and overall survival (OS). Multivariate Cox regression analysis confirmed that miR-15a-5p overexpression is a significant unfavorable prognosticator of DFS in colorectal adenocarcinoma, independent of other established prognostic factors plus treatment of patients. Importantly, miR-15a-5p overexpression retains its unfavorable prognostic value in patients with T3 colorectal adenocarcinoma and in those without distant metastasis (M0). More importantly, the cumulative DFS probability of patients with early stage disease was significantly lower for those with colorectal adenocarcinoma overexpressing miR-15a-5p.

Discussion

In conclusion, elevated expression of the cancer-associated miR-15a-5p predicts poor DFS and OS of colorectal adenocarcinoma patients. The prognostic value of miR-15a-5p expression regarding DFS is independent of clinicopathological factors currently used for colorectal adenocarcinoma prognosis.

Nur mit Berechtigung zugänglich

Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin. 2010;60(2):99–119. doi:10.3322/caac.20063.CrossRefPubMed

Boyle P, Levin B. Colorectal cancer. In: World cancer report. Lyon, France: International Agency for Research on Cancer; 2008. p. 374–8.

Muto T, Bussey HJ, Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975;36(6):2251–70.CrossRefPubMed

Schoen RE. Families at risk for colorectal cancer: risk assessment and genetic testing. J Clin Gastroenterol. 2000;31(2):114–20.CrossRefPubMed

Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.CrossRefPubMed

Steinberg SM, Barkin JS, Kaplan RS, Stablein DM. Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience. Cancer. 1986;57(9):1866–70.CrossRefPubMed

Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004;54(6):295–308 (pii 54/6/295).CrossRefPubMed

Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69. doi:10.1038/nrc1840.CrossRefPubMed

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi:10.1038/nrc1997.CrossRefPubMed

10.

Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature. 2008;455(7209):64–71. doi:10.1038/nature07242.CrossRefPubMedPubMedCentral

11.

Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomark Prev. 2011;20(7):1272–86. doi:10.1158/1055-9965.epi-11-0035.CrossRef

12.

Rapti SM, Kontos CK, Papadopoulos IN, Scorilas A. High miR-96 levels in colorectal adenocarcinoma predict poor prognosis, particularly in patients without distant metastasis at the time of initial diagnosis. Tumour Biol. 2016;. doi:10.1007/s13277-016-5023-0.PubMed

13.

Rapti SM, Kontos CK, Papadopoulos IN, Scorilas A. Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients. Clin Chem Lab Med. 2014;52(8):1217–27. doi:10.1515/cclm-2013-0950.CrossRefPubMed

14.

Adamopoulos PG, Kontos CK, Rapti SM, Papadopoulos IN, Scorilas A. miR-224 overexpression is a strong and independent prognosticator of short-term relapse and poor overall survival in colorectal adenocarcinoma. Int J Oncol. 2015;46(2):849–59. doi:10.3892/ijo.2014.2775.PubMed

15.

Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8(7):523–34. doi:10.1038/nrc2439.CrossRefPubMed

16.

Ramsay RG, Thompson MA, Hayman JA, Reid G, Gonda TJ, Whitehead RH. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992;3(10):723–30.PubMed

17.

Cross RS, Malaterre J, Davenport AJ, Carpinteri S, Anderson RL, Darcy PK, et al. Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin Transl Immunol. 2015;4(1):e30. doi:10.1038/cti.2014.29.CrossRef

18.

Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M, et al. c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001;158(4):1289–99.CrossRefPubMedPubMedCentral

19.

Luo Q, Li X, Li J, Kong X, Zhang J, Chen L, et al. MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013;43(4):1212–8. doi:10.3892/ijo.2013.2034.PubMed

20.

Alderman C, Sehlaoui A, Xiao Z, Yang Y. MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene. Tumour Biol. 2016;. doi:10.1007/s13277-016-5271-z.PubMed

21.

Venza I, Visalli M, Beninati C, Benfatto S, Teti D, Venza M. IL-10Ralpha expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma. BMC Med Genomics. 2015;8:81. doi:10.1186/s12920-015-0156-3.CrossRefPubMedPubMedCentral

22.

Liu X, Wang L, Li H, Lu X, Hu Y, Yang X, et al. Coactivator-associated arginine methyltransferase 1 targeted by miR-15a regulates inflammation in acute coronary syndrome. Atherosclerosis. 2014;233(2):349–56. doi:10.1016/j.atherosclerosis.2014.01.039.CrossRefPubMed

23.

Xin C, Buhe B, Hongting L, Chuanmin Y, Xiwei H, Hong Z, et al. MicroRNA-15a promotes neuroblastoma migration by targeting reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and regulating matrix metalloproteinase-9 expression. FEBS J. 2013;280(3):855–66. doi:10.1111/febs.12074.PubMed

24.

Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol. 2011;9(2):119–23. doi:10.1038/nrclinonc.2011.157.CrossRefPubMed

25.

Shi R, Chiang VL. Facile means for quantifying microRNA expression by real-time PCR. Biotechniques. 2005;39(4):519–25.CrossRefPubMed

26.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8. doi:10.1006/meth.2001.1262S1046-2023(01)91262-9.CrossRefPubMed

27.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7):RESEARCH0034.CrossRefPubMedPubMedCentral

28.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.CrossRefPubMed

29.

Christodoulou S, Alexopoulou DK, Kontos CK, Scorilas A, Papadopoulos IN. Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. Tumour Biol. 2014;35(5):4673–85. doi:10.1007/s13277-014-1612-y.CrossRefPubMed

30.

Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10(21):7252–9. doi:10.1158/1078-0432.CCR-04-0713.CrossRef

31.

Cancer Genome Atlas. N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. doi:10.1038/nature11252.CrossRef

32.

Dong Y, Yu J, Ng SS. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer. Cancer Manag Res. 2014;6:405–22. doi:10.2147/cmar.s35164.PubMedPubMedCentral

33.

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(33):5313–27. doi:10.1200/JCO.2006.08.2644.CrossRef

34.

Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9(7):489–99. doi:10.1038/nrc2645.CrossRefPubMed

35.

Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102. doi:10.1186/1476-4598-8-102.CrossRefPubMedPubMedCentral

36.

Wang J, Du Y, Liu X, Cho WC, Yang Y. MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed Res Int. 2015;2015:823620. doi:10.1155/2015/823620.PubMedPubMedCentral

37.

Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18(3):244–52. doi:10.1097/PPO.0b013e318258b78f.CrossRefPubMedPubMedCentral

38.

Menendez P, Villarejo P, Padilla D, Menendez JM, Rodriguez-Montes JA. Implications of the histological determination of microRNAs in the screening, diagnosis and prognosis of colorectal cancer. J Surg Oncol. 2013;108(1):70–3. doi:10.1002/jso.23344.CrossRefPubMed

39.

Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116. doi:10.3389/fgene.2013.00116.PubMedPubMedCentral

40.

Bartley AN, Yao H, Barkoh BA, et al. Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17(23):7283–93. doi:10.1158/1078-0432.ccr-11-1452.CrossRef

41.

Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739–45. doi:10.1136/gut.2011.239236.CrossRefPubMed

42.

Xiao YF, Yong X, Fan YH, Lu MH, Yang SM, Hu CJ. microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (review). Oncol Rep. 2013;30(2):535–44. doi:10.3892/or.2013.2525.PubMed

43.

Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, Pallone F, et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol. 2011;46(12):1391–402. doi:10.1007/s00535-011-0456-0.CrossRefPubMed

44.

Pichler M, Stiegelbauer V, Vychytilova-Faltejskova P, et al. Genome-wide miRNA analysis identifies miR-188-3p as a novel prognostic marker and molecular factor involved in colorectal carcinogenesis. Clin Cancer Res: Off J Am Assoc Cancer Res. 2016;. doi:10.1158/1078-0432.CCR-16-0497.

45.

Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101(9):2999–3004.CrossRefPubMedPubMedCentral

46.

Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102(39):13944–9. doi:10.1073/pnas.0506654102.CrossRefPubMedPubMedCentral

47.

Takahashi C, Sheng Z, Horan TP, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA. 1998;95(22):13221–6.CrossRefPubMedPubMedCentral

48.

Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 2001;107(6):789–800.CrossRefPubMed

49.

Takenaka K, Ishikawa S, Kawano Y, et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer. 2004;40(10):1617–23. doi:10.1016/j.ejca.2004.02.028.CrossRefPubMed

50.

Span PN, Sweep CG, Manders P, Beex LV, Leppert D, Lindberg RL. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer. 2003;97(11):2710–5. doi:10.1002/cncr.11395.CrossRefPubMed

51.

Masui T, Doi R, Koshiba T, Fujimoto K, Tsuji S, Nakajima S, et al. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9(5):1779–84.

52.

Simizu S, Takagi S, Tamura Y, Osada H. RECK-mediated suppression of tumor cell invasion is regulated by glycosylation in human tumor cell lines. Cancer Res. 2005;65(16):7455–61. doi:10.1158/0008-5472.CAN-04-4446.CrossRefPubMed

53.

Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett. 2014;588(1):99–104. doi:10.1016/j.febslet.2013.11.014.CrossRefPubMed

54.

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118–26. doi:10.1002/ijc.25007.CrossRefPubMed

55.

Xiao G, Tang H, Wei W, Li J, Ji L, Ge J. Aberrant expression of MicroRNA-15a and MicroRNA-16 synergistically associates with tumor progression and prognosis in patients with colorectal cancer. Gastroenterol Res Pract. 2014;2014:364549. doi:10.1155/2014/364549.CrossRefPubMedPubMedCentral

56.

Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14(5):844–52. doi:10.1261/rna.939908.CrossRefPubMedPubMedCentral

57.

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611–22. doi:10.1373/clinchem.2008.112797.CrossRefPubMed

58.

Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271–7. doi:10.1038/nm.1880.CrossRefPubMed

59.

Tian R, Liu T, Qiao L, Gao M, Li J. Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma. Int J Clin Exp Pathol. 2015;8(3):3097–103.PubMedPubMedCentral

60.

Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA. 2008;105(13):5166–71.CrossRefPubMedPubMedCentral

Titel: miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma
verfasst von: Christos K. Kontos
Panagiotis Tsiakanikas
Margaritis Avgeris
Iordanis N. Papadopoulos
Andreas Scorilas
Publikationsdatum: 01.08.2017
Verlag: Springer International Publishing
Erschienen in: Molecular Diagnosis & Therapy / Ausgabe 4/2017
Print ISSN: 1177-1062
Elektronische ISSN: 1179-2000
DOI: https://doi.org/10.1007/s40291-017-0270-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma